Refine
Year of publication
Language
- English (1191)
Has Fulltext
- yes (1191)
Is part of the Bibliography
- no (1191)
Keywords
- Heavy Ion Experiments (21)
- Hadron-Hadron scattering (experiments) (12)
- Hadron-Hadron Scattering (11)
- LHC (9)
- Heavy-ion collision (6)
- Heavy-ion collisions (5)
- ALICE experiment (4)
- Collective Flow (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- ALICE (3)
- Diffraction (3)
- Elastic scattering (3)
- Heavy Ions (3)
- Heavy Quark Production (3)
- Jets and Jet Substructure (3)
- pp collisions (3)
- Beam Energy Scan (2)
- Beauty production (2)
- Charm physics (2)
- Chiral Magnetic Effect (2)
- Collectivity (2)
- Correlation (2)
- Elliptic flow (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- Polarization (2)
- QCD (2)
- Quarkonium (2)
- RHIC (2)
- STAR (2)
- Shear viscosity (2)
- Single electrons (2)
- 900 GeV (1)
- ALICE detector (1)
- Advanced biliary tract cancer (1)
- Anti-kaon–nucleon physics (1)
- Anti-nuclei (1)
- B-slope (1)
- BTC (1)
- Beam energy scan (1)
- Boosted Jets (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charged-particle multiplicity (1)
- Charm quark spatial diffusion coefficient (1)
- Charmonia (1)
- Chiral magnetic effect (1)
- Coalescence (1)
- Cold nuclear matter effects (1)
- Collective Flow, (1)
- Comparison with QCD (1)
- Critical point (1)
- Croatia (1)
- Cybertaxonomy (1)
- Deuteron production (1)
- Di-hadron correlations (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Flow (1)
- Forward physics (1)
- Groomed jet radius (1)
- HBT (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hand-foot syndrome (1)
- Hard Scattering (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-Ion Collision (1)
- Heavy-flavor decay electron (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion (1)
- Hif1α (1)
- Higher moments (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Interference fragmentation function (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- J/ψ suppression (1)
- Jet Physics (1)
- Jet Substructure (1)
- Jet substructure (1)
- Kaonic nuclei (1)
- Low energy QCD (1)
- Material budget (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multiple parton interactions (1)
- Neural network (1)
- Nonflow (1)
- Nuclear modification factor (1)
- PDGFRβ (1)
- PYTHIA (1)
- Partial wave analysis (1)
- Particle and Resonance Production (1)
- Pb–Pb (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Proton-proton collisions (1)
- Proton–proton (1)
- Proton–proton collisions (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Rapidity Range (1)
- Relativistic heavy ion physics (1)
- Relativistic heavy-ion collisions (1)
- Resolution Parameter (1)
- Single muons (1)
- SoftDrop (1)
- Sorafenib (1)
- Spin alignment (1)
- Splitting function (1)
- Systematic Uncertainty (1)
- TR (1)
- Thermal model (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Transversity (1)
- Trigger (1)
- VEGFR-2 (1)
- VEGFR-3 (1)
- Vector Boson Production (1)
- Xenon-based gas mixture (1)
- alleles (1)
- anisotropy (1)
- apparent diffusion constant (1)
- autism spectrum disorder (1)
- autistic disorder (1)
- biomarker (1)
- biospeleology (1)
- burnout (1)
- c-kit (1)
- caves (1)
- copy number polymorphism (1)
- cross-cultural leadership (1)
- cross-cultural study (1)
- dE/dx (1)
- data integration (1)
- detector (1)
- diffusion tensor imaging (1)
- ectosomes (1)
- everolimus (1)
- exhaustion (1)
- exosomes (1)
- experimental results (1)
- extracellular vesicles (1)
- fibre tracking (1)
- gene sequence data (1)
- genes (1)
- genetics (1)
- genome (1)
- genotype (1)
- genotype determination (1)
- guidelines (1)
- heavy ion experiments (1)
- heavy-ion collisions (1)
- identity leadership (1)
- innovative behavior (1)
- magnetic field gradient (1)
- metastatic renal cell carcinoma (1)
- micro-CT (1)
- microparticles (1)
- microvesicles (1)
- minimal information requirements (1)
- molecular systematics (1)
- multilevel modeling (1)
- p+p collisions (1)
- phase IV (1)
- phenotype (1)
- positive leadership (1)
- ppK − (1)
- quark gluon plasma (1)
- reproducibility (1)
- rigor (1)
- second-line (1)
- single nucleotide polymorphism (1)
- social identification (1)
- spectra (1)
- standardization (1)
- team identification (1)
- Υ suppression (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1089)
- Frankfurt Institute for Advanced Studies (FIAS) (1034)
- Informatik (920)
- Medizin (12)
- Informatik und Mathematik (3)
- Geowissenschaften (2)
- Hochschulrechenzentrum (2)
- Psychologie und Sportwissenschaften (2)
- Biochemie und Chemie (1)
- Biowissenschaften (1)
Background: Since sorafenib has shown activity in different tumour types and gemcitabine regimens improved the outcome for biliary tract cancer (BTC) patients, we evaluated first-line gemcitabine plus sorafenib in a double-blind phase II study.
Patients and methods: 102 unresectable or metastatic BTC patients with histologically proven adenocarcinoma of gallbladder or intrahepatic bile ducts, Eastern Cooperative Oncology Group (ECOG) 0–2 were randomised to gemcitabine (1000 mg/m2 once weekly, first 7-weeks + 1-week rest followed by once 3-weeks + 1-week rest) plus sorafenib (400 mg twice daily) or placebo. Treatment continued until progression or unacceptable toxicity. Tumour samples were prospectively stained for sorafenib targets and potential biomarkers. Serum samples (first two cycles) were measured for vascular endothelial growth factors (VEGFs), vascular endothelial growth factor receptor 2 (VEGFR-2) and stromal cell-derived factor 1 (SDF1)α by enzyme-linked immunosorbent assay (ELISA).
Results: Gemcitabine plus sorafenib was generally well tolerated. Four and three patients achieved partial responses in the sorafenib and placebo groups, respectively. There was no difference in the primary end-point, median progression-free survival (PFS) for gemcitabine plus sorafenib versus gemcitabine plus placebo (3.0 versus 4.9 months, P = 0.859), and no difference for median overall survival (OS) (8.4 versus 11.2 months, P = 0.775). Patients with liver metastasis after resection of primary BTC survived longer with sorafenib (P = 0.019) compared to placebo. Patients who developed hand-foot syndrome (HFS) showed longer PFS and OS than patients without HFS. Two sorafenib targets, VEGFR-2 and c-kit, were not expressed in BTC samples. VEGFR-3 and Hif1α were associated with lymph node metastases and T stage. Absence of PDGFRβ expression correlated with longer PFS.
Conclusion: The addition of sorafenib to gemcitabine did not demonstrate improved efficacy in advanced BTC patients. Biomarker subgroup analysis suggested that some patients might benefit from combined treatment.